1、从红海到蓝海：解码中国自免治疗高潜力靶点By Insight/June,20252025 年 6 月 27 日英文简写英文全称中文全称ADAtopic dermatitis特应性皮炎ALSAmyotrophic Lateral Sclerosis肌萎缩侧索硬化症ARMAntibody-mediated rejection抗体介导排斥反应AsAnkylosing Spondylitis强直性脊柱炎C3GC3 GlomerulopathyC3肾小球病CDCrohns disease克罗恩病FSGSFocal Segmental Glomerulosclerosis局灶节段性肾小球硬化症GDGlom

2、erular Disease肾小球疾病GPPGeneralized Pustular Psoriasis泛发性脓疱型银屑病IBDInflammatory bowel disease炎症性肠病IgANIgA NephropathyIgA肾病ILDInterstitial Lung Disease间质性肺疾病IPFIdiopathic pulmonary fibrosis特发性肺纤维化ITPIdiopathic Thrombocytopenic Purpura免疫性血小板减少症LNLupus nephritis狼疮肾炎MGMyasthenia gravis重症肌无力缩略词表2英文简写英文全称中文全

3、称MPGNMembranoproliferative Glomerulonephritis膜增生性肾小球肾炎MSMultiple sclerosis多发性硬化PMNPrimary membranous nephropathy原发性膜性肾病PNHParoxysmal Nocturnal Hemoglobinuria阵发性睡眠性血红蛋白尿症PPFProgressive Pulmonary Fibrosis进行性肺纤维化PsAPsoriatic Arthritis银屑病关节炎PsOPlaque Psoriasis斑块状银屑病RARheumatoid Arthritis类风湿关节炎SLESystemi

4、c Lupus Erythematosus系统性红斑狼疮SSSjgrens Syndrome干燥综合征SScSystemic Sclerosis系统性硬化症T1DMType1 Diabetes Mellitus1型糖尿病TGTransplant Kidney Disease慢性移植肾病UCUlcerative colitis溃疡性结肠炎HSHidradenitis Suppurativa化脓性汗腺炎自免领域概览01中国自免疾病药物市场规模4自免药物销量与肿瘤分庭抗礼，中国将成为自免药物的全球增速引擎数据来源：Insight 数据库，沙利文，Autoimmunity Reviews；数据统计截止

5、 2025.06.20药品名称靶点企业FDA首次批准时间销售额（亿美元）疾病领域KeytrudaPD-1默沙东2014294.82肿瘤SemaglutideGLP1R诺和诺德2017292.96内分泌TirzepatideGLP1RGIPR礼来2022164.66内分泌DupixentIL-4R赛诺菲2017140.89免疫BiktarvyReverse transcriptase/RNaseH吉利德2018134.23感染EliquisFactor XaBMS/辉瑞2012133.33心血管JardianceSGLT2BI/礼来2014123.48内分泌与代谢SkyriziIL-23p19艾

6、伯维2019117.18免疫DarzalexCD38强生2015116.70肿瘤StelaraIL12 p40强生2009103.61免疫TrikaftaCFTR福泰2019102.39罕见病OpdivoPD-1BMS2014101.79肿瘤单位：亿美元2024 年全球销售额 Top12自免疾病发病机制具有相关性度普利尤单抗已获批适应症USEUJPCN特应性皮炎嗜酸性粒细胞哮喘哮喘慢性鼻窦炎伴鼻息肉病嗜酸性粒细胞性食管炎结节性痒疹慢性自发性荨麻疹嗜酸性粒细胞型慢性阻塞性肺疾病大疱性类天疱疮25252831405065821031271551882242632019202020212022202